A Phase IIb, Multi-National, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) (BENEFIT-ALS)

Trial Profile

A Phase IIb, Multi-National, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) (BENEFIT-ALS)

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Nov 2017

At a glance

  • Drugs Tirasemtiv (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Therapeutic Use
  • Acronyms BENEFIT-ALS
  • Sponsors Cytokinetics
  • Most Recent Events

    • 30 Nov 2017 According to a Cytokinetics media release, retrospective analysis data from EMPOWER, BENEFIT-ALS and Open-Access ALS Clinical Trials (PRO-ACT) database were published in the Journal of the American Medical Association (JAMA) Neurology.
    • 30 Nov 2017 Retrospective data was published in a Cytokinetics media release.
    • 28 Apr 2016 Results published in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, according to a Cytokinetics Inc. media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top